Cocrystal Pharma Shares Outstanding 2008-2021 | COCP

Cocrystal Pharma shares outstanding from 2008 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Cocrystal Pharma Annual Shares Outstanding
(Millions of Shares)
2020 55
2019 32
2018 28
2017 24
2016 24
2015 21
2014 328
2013 57
2012 62
2011 50
2010 45
2009 4
2008 4
2007 3
Cocrystal Pharma Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 87
2021-03-31 71
2020-12-31 55
2020-09-30 58
2020-06-30 52
2020-03-31 42
2019-12-31 32
2019-09-30 32
2019-06-30 32
2019-03-31 30
2018-12-31 28
2018-09-30 30
2018-06-30 28
2018-03-31 24
2017-12-31 24
2017-09-30 24
2017-06-30 24
2017-03-31 24
2016-12-31 24
2016-09-30 707
2016-06-30 706
2016-03-31 697
2015-12-31 21
2015-09-30 697
2015-06-30 697
2015-03-31 440
2014-12-31 328
2014-09-30 327
2014-06-30 327
2014-03-31 324
2013-12-31 57
2013-09-30 57
2013-06-30 57
2013-03-31 57
2012-12-31 62
2012-09-30 69
2012-06-30 59
2012-03-31 56
2011-12-31 50
2011-09-30 67
2011-06-30 41
2011-03-31 45
2010-12-31 45
2010-09-30 38
2010-06-30 38
2010-03-31 38
2009-12-31 4
2009-09-30 4
2009-06-30 4
2009-03-31 4
2008-12-31 4
2008-09-30 4
2008-06-30 4
2008-03-31 4
2007-09-30 4
2007-06-30 3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.103B $0.002B
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71